When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
AKRO - Akero's lead drug successful in mid-stage NASH study
Akero Therapeutics Inc.
Akero Therapeutics (NASDAQ:AKRO) announces positive results from a Phase 2 clinical trial, BALANCED, evaluating lead candidate AKR-001 patients with F1-F4 (minimal fibrosis to severe fibrosis) nonalcoholic steatohepatitis (NASH).
More news on: Akero Therapeutics, Inc., Healthcare stocks news, Stocks on the move,